Galectin-3 Predicts Cardiovascular Disease Risk in Diabetic Patients
|
By LabMedica International staff writers Posted on 19 Oct 2020 |
|
Image: An ELISA kit for Galectin-3 which can predict cardiovascular events in patients with type-2 diabetes (Photo courtesy of Immuno-Biological Laboratories).
Cardiovascular disease (CVD) is a general term for conditions affecting the heart or blood vessels. It's usually associated with a build-up of fatty deposits inside the arteries (atherosclerosis) and an increased risk of blood clots. Type 2 diabetes (T2D) can lead to early and severe atherosclerosis.
Galectin-3 (Gal-3) is also a member of the beta-galactoside-binding protein family that plays an important role in cell-cell adhesion, cell-matrix interactions, macrophage activation, angiogenesis, metastasis, and apoptosis. Galectin-3 is a novel prognostic biomarker with high predictive value for cardiovascular mortality and re-hospitalization in heart failure patients.
Medical scientists at the Fundacion Jimenez Diaz University Hospital (Madrid, Spain) studied 964 patients with coronary artery disease. They assessed baseline galectin-3, monocyte chemoattractant protein-1 (MCP-1) and N-terminal fragment of brain natriuretic peptide (NT-proBNP) plasma levels in the patients. Male patients were 75% in T2D group and 76.6% in the non-T2D group and mean age was 61.0 and 60.0 years, respectively. The team identified 232 patients with T2D. The patients were followed up for a median of 5.39 years.
The scientists reported that patients with T2D showed higher MCP-1(144 versus 133 pg/mL) and galectin-3 (8.3 versus 7.8 ng/mL) levels. Galectin-3 levels were associated with increased risk of the primary outcome in T2D patients (Hazard ratio [HR] = 1.57), along with a history of cerebrovascular events. NT-proBNP and MCP-1, but not galectin-3, were related to increased risk of the event in non-diabetic patients (HR = 1.21 and HR = 1.23 respectively), along with male sex and age. Galectin-3 was also the only biomarker that predicted the development of acute ischemic events and heart failure or death in T2D patients, while in non-diabetics MCP-1 and NT-proBNP, respectively, predicted these events.
The authors concluded that in patients with coronary artery disease (CAD), cardiovascular events are predicted by galectin-3 plasma levels in patients with T2D, and by MCP-1 and NT-proBNP in those without T2D. Galectin-3 predicts cardiovascular events in patients with type-2 diabetes. The study was presented at the European Society of Cardiology (ESC) Congress 2020 held virtually August 29 to September 1, 2020.
Related Links:
Fundacion Jimenez Diaz University Hospital
Galectin-3 (Gal-3) is also a member of the beta-galactoside-binding protein family that plays an important role in cell-cell adhesion, cell-matrix interactions, macrophage activation, angiogenesis, metastasis, and apoptosis. Galectin-3 is a novel prognostic biomarker with high predictive value for cardiovascular mortality and re-hospitalization in heart failure patients.
Medical scientists at the Fundacion Jimenez Diaz University Hospital (Madrid, Spain) studied 964 patients with coronary artery disease. They assessed baseline galectin-3, monocyte chemoattractant protein-1 (MCP-1) and N-terminal fragment of brain natriuretic peptide (NT-proBNP) plasma levels in the patients. Male patients were 75% in T2D group and 76.6% in the non-T2D group and mean age was 61.0 and 60.0 years, respectively. The team identified 232 patients with T2D. The patients were followed up for a median of 5.39 years.
The scientists reported that patients with T2D showed higher MCP-1(144 versus 133 pg/mL) and galectin-3 (8.3 versus 7.8 ng/mL) levels. Galectin-3 levels were associated with increased risk of the primary outcome in T2D patients (Hazard ratio [HR] = 1.57), along with a history of cerebrovascular events. NT-proBNP and MCP-1, but not galectin-3, were related to increased risk of the event in non-diabetic patients (HR = 1.21 and HR = 1.23 respectively), along with male sex and age. Galectin-3 was also the only biomarker that predicted the development of acute ischemic events and heart failure or death in T2D patients, while in non-diabetics MCP-1 and NT-proBNP, respectively, predicted these events.
The authors concluded that in patients with coronary artery disease (CAD), cardiovascular events are predicted by galectin-3 plasma levels in patients with T2D, and by MCP-1 and NT-proBNP in those without T2D. Galectin-3 predicts cardiovascular events in patients with type-2 diabetes. The study was presented at the European Society of Cardiology (ESC) Congress 2020 held virtually August 29 to September 1, 2020.
Related Links:
Fundacion Jimenez Diaz University Hospital
Gold Member
Troponin T QC
Troponin T Quality Control
New
Centromere B Assay
Centromere B Test
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
